Open-house rebate agreement for multiple X-ray contrast agents
Original notice title
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen im Rahmen eines sog. Open-House-Modells zu diversen Röntgenkontrastmitteln (ATC-Code nach WHO: V08)
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
Submissions are only accepted by the monthly cut-off; late receipt is pushed to the next month, which can delay market...
Only the explicitly named contractor categories may participate.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Mar 2027
- Non-exclusive supply/rebate agreement for pharmaceutical products, specifically X-ray contrast agents under ATC code V08.
- Open-house model with no individual negotiations and no delivery exclusivity.
Show full summary
This is a German open-house supply arrangement for non-exclusive rebate agreements on multiple X-ray contrast agents (CPV 33600000) for AOK PLUS and associated health insurers. The notice states that participation is open to qualifying pharmaceutical companies, wholesalers, and public pharmacies, with no individual negotiations and no exclusivity. The procedure is unusual because the notice explicitly says it is not a public contract within the meaning of procurement law, although it is published in TED for transparency. Participation documents must be submitted electronically via DTVP after access approval, and the first submission deadline is 17 February 2025; afterwards, submissions are accepted by the 15th of each month until the agreement ends on 31 March 2027. No contract value is provided.
Risks
Submissions are only accepted by the monthly cut-off; late receipt is pushed to the next month, which can delay market...
Only the explicitly named contractor categories may participate.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Only pharmaceutical companies, wholesalers, or public pharmacies may act as contractors.
Eligibility
- Required submissions include the completed declaration of no exclusion grounds under §§ 123, 124 GWB.
Administrative
- Participation documents must be submitted fully and on time by the applicable monthly deadline.
Buyer
Location
Erfurt, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Open-house rebate agreement for multiple X-ray contrast agents
Open-house, non-exclusive rebate agreement for a broad set of contrast media under ATC V08. The lot covers multiple named substances including Amidotrizoesäure, Ioxitalaminsäure, Iohexol, Iopamidol, Iopromid, Ioversol, Iodixanol, Iomeprol, Iobitridol, Bariumsulfat, and several gadolinium-based agents. The notice states that purchase volumes are unknown and minimum volumes are not guaranteed. Performance/place of use is stated as Dresden, Germany, but the agreement applies nationally within Germany.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht-exklusiver Rabattvereinbarungen im Rahmen eines sog. Open-House-Modells zu diversen Röntgenkontrastmitteln (ATC-Code nach WHO: V08)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 21 Jan 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 43670-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Belgium – Pharmaceutical products – Antimycotica
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
Submissions are only accepted by the monthly cut-off; late receipt is pushed to the next month, which can delay market...
Only the explicitly named contractor categories may participate.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications